Pharmaceuticals News and Research

RSS

Opinion pieces, blog react to new public-private NTD initiative

Pharmaceutical company heads and global health leaders gathered at a conference on Monday in London to announce the formation of a large public-private partnership to fight neglected tropical diseases (NTDs) and endorse the "London Declaration on Neglected Tropical Diseases", in which they pledged to work together and track progress.

1 Feb 2012

TGen, UA receive NFCR grant to study targeted pancreatic cancer therapies

The Translational Genomics Research Institute (TGen) and the University of Arizona (UA) have received a three-year, $600,000 grant to study targeted cancer therapies from the National Foundation for Cancer Research.

1 Feb 2012

Hand hygiene, surgical masks can cut spread of flu-like illnesses upto 75%

Masks and hand hygiene could cut the spread of flu-like symptoms up to 75 percent, a University of Michigan study found.

1 Feb 2012

NIAID, Aeras partner for Phase II clinical trial of TB vaccine

Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

1 Feb 2012

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors.

1 Feb 2012

New combination clinical trial may improve outcome for cancer surgery patients

The week before and two weeks after surgery are a critical period for the long-term survival rate of cancer patients. Physiological and psychological stresses caused by the surgery itself can inhibit the body's immune responses, heightening vulnerability to tumor progression and spreading.

1 Feb 2012

Vertex receives FDA approval for Kalydeco to treat rare form of CF

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

1 Feb 2012

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

1 Feb 2012

Milestone for Starpharma's drug delivery program

Starpharma Holdings today released animal data which demonstrated that its dendrimer-docetaxel formulation applying Starpharma’s dendrimer technology to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere®) in a breast cancer model.

1 Feb 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012

Sigma-Aldrich acquires BioReliance

Sigma-Aldrich Corporation, a leading Life Science and High Technology company, announced it has completed its acquisition of BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash, subject to normal post-closing adjustments.

31 Jan 2012

$Anti-malarial treatment available to millions of poor Nigerians at a fraction of its normal cost$

Anti-malarial treatment available to millions of poor Nigerians at a fraction of its normal cost

Millions of poor Nigerians will gain access to the most effective combination treatment for malaria at a fraction of its current cost, following the successful conclusion of negotiations between the United Kingdom Department for International Development (DFID) funded Partnership for Transforming Health Systems (PATHS2) and a variety of international and national stakeholders in Nigeria this week.

31 Jan 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

Bioton and Actavis form joint venture

Actavis and Bioton announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins.

31 Jan 2012

Indoco, DSM sign agreement for commercial cooperation for eight APIs

Royal DSM N.V., today announced the signing of an agreement with Indoco Remedies Limited, Mumbai, India, for commercial cooperation for eight Active Pharmaceutical Ingredients (APIs). The alliance came into effect in January 2012.

31 Jan 2012

Viewpoints: Contraceptive controversy; Revising mental health definitions

It was good news that the Obama administration withstood pressure from Roman Catholic bishops and social conservatives to deny contraceptive coverage for millions of American women who work for religiously affiliated employers. Kathleen Sebelius, the Health and Human Services secretary, rejected broad exemptions from a new rule requiring all health plans to cover birth control, without a deductible or co-payment.

31 Jan 2012

Large public-private partnership announced to speed progress against NTDs

Thirteen pharmaceutical companies; the governments of the U.S., U.K. and United Arab Emirates; the Bill & Melinda Gates Foundation; the WHO; the World Bank; the Drugs for Neglected Diseases initiative (DNDi); and other global health organizations "announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade," according to a press release from Global Health Strategies.

31 Jan 2012

Janssen, Orexo to end OX-CLI/OX-ESI research collaboration and license agreement

Orexo AB and Janssen Pharmaceuticals, Inc., formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV, have decided to end their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs and a third, undisclosed Janssen program.

31 Jan 2012

Study pinpoints genetic factors behind increased ALL risk in Hispanic children

Hispanic children are more likely than those from other racial and ethnic backgrounds to be diagnosed with acute lymphoblastic leukemia (ALL) and are more likely to die of their disease. Work led by St. Jude Children's Research Hospital scientists has pinpointed genetic factors behind the grim statistics.

31 Jan 2012

Abbott, DNDi partner to research on new treatments for NTDs

The Drugs for Neglected Diseases initiative (DNDi) and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness.

31 Jan 2012